Complete histologic response to neoadjuvant pembrolizumab in high-risk stage IIC melanoma of the nasal ala: A case report
Emma Clochard, Julien Anriot, Mona Amini-Adle, Eve-Marie Neidhardt · 2026
Read Complete histologic response to neoadjuvant pembrolizumab in high-risk stage IIC melanoma of the nasal ala: A case report by Emma Clochard, Julien Anriot, Mona Amini-Adle, Eve-Marie Neidhardt (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13625884.txt.
Description
Emma Clochard and co-authors report a melanoma erased before surgery in a 2026 case paper. Melanoma of the nose wing is usually cut out with wide margins. On the face, that standard operation can badly disfigure.
Their patient was a fifty-two-year-old man with a thick, ulcerated tumor and no spread on scans. The tumor board chose off-label pembrolizumab first, three cycles of the immune drug. Photos show the raised lesion before treatment and its state after. When the tissue was later examined, the response proved complete under the microscope: no living tumor remained. The case argues for drug-first treatment in select facial melanomas where the knife costs most.
Catalog record
| CREATOR | Emma Clochard, Julien Anriot, Mona Amini-Adle, Eve-Marie Neidhardt |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |